Lung cancer is the leading cause of cancer-related death worldwide, and non--small cell lung cancer (NSCLC) is the most common type of this disease[@b1][@b2]. With comprehensive understanding of the genetic alteration of lung cancer, many onco-targeted drugs had been developed, and great achievements have been attained in patients with advanced disease[@b3][@b4][@b5][@b6][@b7][@b8].

Patients with activating *EGFR* mutations are identified in \~20% of lung adenocarcinomas in Western countries[@b9] and 40\~60% of lung adenocarcinomas in East Asia[@b10][@b11][@b12]. These mutations mainly consist of in-frame deletions in exon 19 (\~50%) and the L858R point mutation in exon 21 (\~40%)[@b9], and they are associated with a favorable response to the EGFR tyrosine kinase inhibitors (EGFR-TKI), such as gefitinib and erlotinib[@b5][@b13]. Exon 19 and 21 are located in the intracellular kinase domain of *EGFR*, which also includes exons 18 and 20[@b4].

Both point mutations in exon 18 and insertion mutations in exon 20 are relatively infrequent, respectively, at 3% and 5% of the *EGFR* mutations[@b14][@b15]. With more than 1.6 million cases of lung cancer diagnosed and 1.3 million deaths per year[@b16], even small subgroups of NSCLC contribute to significant morbidity and mortality. Insertions in exon 20 of *EGFR* have been reported to be associated with resistance to EGFR-TKI and poor prognosis in NSCLC patients[@b17][@b18][@b19][@b20]. Single point mutations in exon 18 mainly consist of E709X and G719X mutations. Those mutations have been identified in several previous studies with limited sample sizes[@b11][@b21][@b22][@b23]. However, other complex *EGFR* mutations that included not only single point mutations in exon 18 but also other genetic alterations in the EGFR kinase domain were not well characterized. In addition, the relationship between the complex mutations and sensitivity to EGFR-TKI therapy has not been completely elucidated.

In this study, we retrospectively investigated the frequency, molecular spectrum and clinicopathologic characteristics of patients with *EGFR* exon 18 mutations in a large cohort of patients with lung adenocarcinomas. We also analyzed lung cancer patients with single or complex *EGFR* exon 18 mutations and their correlation to treatment outcome with EGFR-TKI.

Results
=======

A total of 1,201 patients with lung adenocarcinomas were screened for *EGFR* mutation status. Of those, 737 (61.4%) patients were found to harbor mutations in *EGFR*. Among the patients who harbored *EGFR* mutations, we detected 34 (4.6% of 737) patients with mutations in the *EGFR* exon 18,661 (89.7%) cases with classic activating mutations (exon 19 deletions and L858R point mutation), and 42 patients harbored other rare mutations.

Of the 34 patients with *EGFR* exon 18 mutations, 27 (79.4%) were women, and 29 (85.3%) were never-smokers. The amino acid sequence of the *EGFR* exon 18 mutations included 23 different variants, and only 4 of 23 variants occurred more than once. Seventeen (50.0%) variants involved the G719 locus, 7 (20.6%) variants involved the E709 locus and 4 (11.8%) involved both G719 and E709, with 6 (17.6%) others. The predominant pathological subtype included 16 (47.1%) with acinar tumors, 8 (23.5%) with papillary tumors, 4 (11.8%) with solid tumors, 4 (11.8%) with lepidic tumors and 2 (5.9%) with minimally invasive adenocarcinoma (MIA) ([Table 1](#t1){ref-type="table"}).

The clinicopathologic characteristics for each individual patient who carried mutations in the *EGFR* exon 18 are shown in [Table 1](#t1){ref-type="table"}. No significant differences were identified between the patients carrying a mutation in exon 18 and those with activating mutations regarding age, smoking status, stage, tumor size and differentiation ([Table 2](#t2){ref-type="table"}).

A total of 33 patients with *EGFR* exon 18 mutations and 489 patients with classic activating mutations diagnosed from October 2007 to March 2011 were included for survival analysis. The median follow-up duration of these patients was 33 months (range: 1--78 months). There were no significant differences in RFS (*p* = 0.652, [Fig. 1A](#f1){ref-type="fig"}) and OS (*p* = 0.984, [Fig. 1B](#f1){ref-type="fig"}) between patients with *EGFR* exon 18 mutations and patients with classic activating mutations. We further divided patients with exon 18 mutations into two subgroups: patients with single *EGFR* exon 18 mutations and those with complex *EGFR* exon 18 mutations (*EGFR* exon 18 mutations + other *EGFR* mutations). In univariate analysis, although there were no significant differences in RFS between those two subgroups (log-rank *p* = 0.246, [Fig. 1C](#f1){ref-type="fig"}) and between single *EGFR* exon 18 mutations and classic mutations (log-rank *p* = 0.310, [Fig. 1C](#f1){ref-type="fig"}), the OS of patients with single *EGFR* exon 18 mutations was much worse than those with complex *EGFR* exon 18 mutations (log-rank *p* = 0.002, [Fig. 1D](#f1){ref-type="fig"}) or those with classic mutations (log-rank *p* = 0.014, [Fig. 1D](#f1){ref-type="fig"}). Gender (*p* = 0.003), smoking history (*p* \< 0.001), tumor size (*p* \< 0.001), stage (*p* \< 0.001) and differentiation (*p* \< 0.001) were significantly associated with RFS. Smoking history (*p* = 0.017), tumor size (*p* \< 0.001), stage (*p* \< 0.001) and differentiation (*p* \< 0.001) were significantly correlated with a worse OS ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). In multivariate analysis incorporating mutation status, gender, age, smoking history, tumor size (≤3 vs. \>3 cm), stage (I vs. II--IV), differentiation (well/moderate vs. poor), smoking history (hazard ratio = 2.184, 95% confidence interval: 1.393--3.422, *p* = 0.001), tumor size (hazard ratio = 1.397, 95% confidence interval: 1.057--1.845, *p* = 0.019), stage (hazard ratio = 4.763, 95% confidence interval: 3.485--6.510, *p* \< 0.001) and differentiation (hazard ratio = 1.608, 95% confidence interval: 1.199--2.156, *p* = 0.002) were the independent predictor of RFS, and single exon 18 mutations (hazard ratio = 2.239, 95% confidence interval: 1.005--4.989, *p* = 0.049), tumor size (hazard ratio = 1.917, 95% confidence interval: 1.247--2.947, *p* = 0.003), stage (hazard ratio = 5.644, 95% confidence interval: 3.064--10.396, *p* \< 0.001) and differentiation (hazard ratio = 2.036, 95% confidence interval: 1.310--3.165, *p* = 0.002) were the independent predictor of OS ([Supplementary Table S2](#S1){ref-type="supplementary-material"}).

Nine patients received platinum-based combination chemotherapies, and one patient received fluorouracil. Of these, two patients received neoadjuvant chemotherapies before surgery, and eight received chemotherapies after disease recurrence. Of the two patients who received neoadjuvant chemotherapies, according to Response Evaluation Criteria in Solid Tumors (RECIST), one had a RECIST stable disease and the other had a RECIST partial response. Of the eight patients receiving chemotherapy, one had a RECIST partial response, two had RECIST stable disease, four had RECIST progressive disease, and one was of unknown status because of loss to follow-up ([Table 1](#t1){ref-type="table"}). The only one patient receiving radiotherapy after disease recurred had a RECIST stable disease ([Table 1](#t1){ref-type="table"}).

After the disease relapsed, five patients with *EGFR* exon 18 mutations received EGFR-TKI therapies, including 2 treated with erlotinib and 3 with gifitinib as first-, second- or third-line therapy. According to RECIST, four patients had a RECIST partial response. The times to progression for these patients were 65.0, 14.8+ 20.7+ and 37.5+ months, respectively, and the overall survival after taking the TKIs were 68+, 14.8+, 29.4+, and 37.5+ months, respectively ([Table 3](#t3){ref-type="table"}). One patient had a RECIST stable disease, and both the RFS and OS were 24.2+ months ([Table 3](#t3){ref-type="table"}).

Discussion
==========

The management of lung adenocarcinomas has been transformed by the identification of targetable oncogenic drivers that confer sensitivity to specific tyrosine kinase inhibitors. Activating mutations in the *EGFR* gene, such as a deletion on exon 19 and a point mutation in exon 21, identifies a distinct subset of lung cancers that are uniquely sensitive to EGFR-TKIs. In the current study, we demonstrated that exon 18 mutations represent an additional target that is sensitive to EGFR-TKI therapy, regardless of less common than classic *EGFR* mutations.

In the current study, five patients who harbored *EGFR* exon 18 mutations had a favorable RFS after receiving the TKI therapies. The response rates (4/5) and RFS of our cohort were greater than those reported by other groups[@b21][@b22][@b24][@b25][@b26]. This may be due to the ethnicity and small sample size of our cohort. In addition, one patient harbored double point mutations (G719S+L861Q) and obtained an amazing RFS of 65 months, which causes us to explore the potential effect of TKI therapies on different *EGFR* mutations. We also found that two patients benefited from TKI therapies after failure to ameliorate the tumor progression by chemotherapies. Furthermore, therapy for one patient failed to ameliorate the tumor progression by radiotherapy and to obtain similar improvement. Taken together, our results suggest that TKI therapies should be considered as a prior choice for advanced lung adenocarcinoma patients with *EGFR* mutations in exon 18.

Although some previous reports showed the discordance of EGFR mutation between primary and metastatic tumors[@b27][@b28], further studies with large sample sizes and studies utilizing the high throughput technology of whole exome sequencing demonstrated that driver events, such as EGFR and BRAF mutations, were highly consistent between primary and metastatic tumors. Given that the samples were obtained mainly by aspiration biopsy and FFPE tissues[@b29][@b30], the quality and quantity might not be enough to obtain an accurate EGFR mutation status.

Survival analysis results showed that there were no significant differences in RFS and OS between *EGFR* mutations in exon 18 and classic activating mutations. A comparison of the Kaplan-Meier curves suggested that the OS of patients with single exon 18 mutations was shorter than those with complex exon 18 mutations or patients with classic *EGFR* mutations. However, there were no significant differences in RFS between patients with single exon 18 mutations and those with complex exon 18 mutations or classic mutations. Our results indicate that single *EGFR* exon 18 mutations may be an indicator of poor prognosis compared with classic activating mutations or complex exon 18 mutations. Further investigations are required to address these differences.

To our knowledge, this report is the first comprehensive study of clinicopathologic features of *EGFR* exon 18 mutations in a large cohort of patients with lung adenocarcinoma. We showed that *EGFR* mutations in exon 18 were present in 2.8% of lung adenocarcinomas and 4.6% of *EGFR* mutations, which were similar to the prevalence of *EGFR* exon 20 insertion mutations in East Asians as we previously reported[@b31]. A limited number of cases with *EGFR* exon 18 mutations had been reported by previous studies[@b22][@b25]. It is therefore difficult to draw conclusions as to their true prevalence, molecular spectrum, and clinicopathologic features. We found 23 kinds of variants of *EGFR* exon 18 mutations in the current study. Of all exon 18 mutations, G719X mutations in *EGFR* exon 18 were the most common variant, and E709X mutations were the second most common, which was similar to a previous report[@b22]. We also showed that patients harboring *EGFR* exon 18 mutation had clinicopathologic characteristics very similar to those with classic *EGFR* activating mutations, which were characterized as being more frequent in females and never smokers[@b10][@b32].

There are several limitations of this study. First, the finding that patients with single exon 18 mutations had a significantly worse OS than those with complex exon 18 mutations was based on a small number of patients, which needs to be validated in a larger series of patients. Second, we conducted cDNA-PCR sequencing as the major experimental method to identify mutations. Results obtained by analyzing corresponding data involving those from the negative EGFR mutations group might change if more sensitive methods, such as the amplification refractory mutation system (ARMS), are used.

In conclusion, our data demonstrated that *EGFR* exon 18 mutations occurred in 2.8% of patients with NSCLCs and 4.6% of patients with *EGFR* mutations. Single *EGFR* exon 18 mutations may be an indicator of poor prognosis compared with classic activating mutations. Given that 4 of 5 patients with *EGFR* mutations in exon 18 had an objective response to the TKIs therapies and a RFS of 65.0, 14.8+, 20.7+, and 37.5+ months in our cohort, we suggest that advanced patients with those mutations should have TKIs as prior therapy.

Methods
=======

Patients and Samples
--------------------

From October 2007 to January 2013, we consecutively collected lung tumors resected at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Inclusion criteria for this study were as follows: (1) patients underwent complete resection with curative intent, and (2) specimens were pathologically confirmed as lung adenocarcinomas with a minimum of 50% of tumor cells and sufficient tissue for comprehensive mutational analyses.

Pathologic slides were reviewed by two certified pathologists (Xuxia Shen and Yuan Li) to classify histologic subtypes of lung adenocarcinomas according to the IASLC/ATS/ERS multidisciplinary classification system[@b33]. The following clinicopathologic parameters for each patient were also collected: gender, age at diagnosis, smoking history, systemic treatment of advanced lung cancers, and pathologic TNM stage in line with the seventh edition of the lung cancer staging system[@b34]. Recurrence-free survival (RFS) and overall survival (OS) of patients diagnosed from October 2007 to March 2011 (because of relatively insufficient follow-up duration) were recorded based on a follow-up clinic visit or a telephone call.

Mutational Analysis
-------------------

After frozen tumor specimens were dissected in TRIzol reagent (Invitrogen, Carlsbad, CA), DNA and RNA were extracted as per standard protocol, and the RNA was reverse transcribed into cDNA by a RevertAid First Strand cDNA Synthesis Kit (Fermentas, EU). *EGFR* (exons 18--21) were amplified by PCR routinely using cDNA. Direct dideoxynucleotide sequencing was then performed to analyze the amplified products. The *EGFR* (exons 18--21) amplified products obtained by PCR using DNA for sequencing were used to confirm the uncommon EGFR mutations. Primers and PCR condition are listed in the [supplementary Table 3](#S1){ref-type="supplementary-material"}.

Statistical Analysis
--------------------

Pearson's χ2 test or Fisher's exact test was used to investigate the correlations between two categorical variables. The association between one categorical variable and one continuous variable was assessed using the independent sample *t*-test. The RFS and OS distribution was analyzed using the Kaplan--Meier method, and log-rank tests were employed for comparisons of RFS or OS between two categories in univariate analysis. Multivariate survival analysis was conducted using the Cox proportional hazards regression (forward likelihood ratio model) to identify independent prognostic factors. Statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) 16.0 software (SPSS Inc., Chicago, IL). All tests were two-tailed. Statistical significance was set at p \< 0.05.

Ethics Statement
----------------

This study was conducted in line with the Helsinki Declaration and approved by the Institutional Review Board of the Fudan University Shanghai Cancer Center. Written informed consent was obtained from each patient to allow their biological samples to be genetically analyzed. The experimental protocol of this study was performed strictly in accordance with the guidelines.
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###### Individual patient characteristics.

  Case    Stage     Mutation type     Mutated   Sex/Age   Smoking   Pathological         Neoadjuvant                 Adjuvant              First-line treatment      Response
  ------ ------- ------------------- --------- --------- --------- -------------- ------------------------- --------------------------- --------------------------- ----------
  1        IV        G719S+L861Q      18, 21     70/F      Never       Acinar               None              Cisplatin + Gemcitabine            Gefitinib              PR
  2        Ia         709ET=\>D         18       51/F      Never        MIA                 None                       None                        None                N/A
  3       IIIa        709ET=\>D         18       43/M      Ever        Acinar               None               Cisplatin + Docetaxel      Cisplatin + Gemcitabine       PD
  4        Ia           G719A           18       71/F      Never      Lepidic               None                       None                        None                N/A
  5        Ib        F723I+L858R      18, 21     58/F      Never       Acinar               None                       None                    Fluorouracil            N/A
  6       IIIa       V689L+L858R      18, 21     43/F      Never      Papillar              None              Cisplatin + Vinorelbine          Radiotherapy             PD
  7        Ib        G719A+I768S      18, 20     77/F      Never      Lepidic               None                       None                        None                N/A
  8        Ib     G719S+del746ELREA   18, 19     60/F      Never       Acinar               None                       None                        None                N/A
  9       IIIa          G719A           18       84/M      Never       Acinar               None                       None                        None                N/A
  10      IIIa       E709K+G719S        18       54/F      Never       Acinar               None              Cisplatin + Gemcitabine              None                N/A
  11      IIIb          G719A           18       64/M      Ever       Papillar              None              Cisplatin + Vinorelbine     Cisplatin + Gemcitabine       PD
  12       Ib        G719A+L861Q      18, 21     74/F      Never       Acinar               None                       None                        None                N/A
  13      IIIa       L692V+L858R      18, 21     63/F      Never       Acinar      Cisplatin + Gemcitabine   Carboplatin + Gemcitabine             None                 PR
  14      IIIa       G719C+S768I      18, 20     77/M      Ever       Papillar              None              Cisplatin + Gemcitabine              None                N/A
  15      IIIa       G719S+T790M      18, 20     66/F      Never       Solid                None                       None              Carboplatin + Gemcitabine      PR
  16       Ia        G719A+S768I      18, 20     62/F      Never      Lepidic               None                       None                        None                N/A
  17       Ia        E709K+L858R      18, 21     53/F      Never       Acinar               None                       None                        None                N/A
  18       IV        E709K+G719C        18       46/F      Never       Acinar               None              Cisplatin + Gemcitabine     Cisplatin + Pemetrexed        PD
  19       Ia         709ET=\>D         18       38/F      Never       Acinar               None                       None                        None                N/A
  20       Ia        Q701L+L858R      18, 21     64/F      Never       Acinar               None                       None                        None                N/A
  21       Ia        G724S+S768I      18, 20     47/F      Never      Papillar              None              Cisplatin + Pemetrexed       Cisplatin + Docetaxel        SD
  22      IIIa        709ET=\>D         18       47/F      Never       Solid                None                       None              Carboplatin + Gemcitabine      PD
  23       Ia        E709K+L858R      18, 21     58/F      Never      Papillar              None                       None                      Gefitinib              PR
  24       IV        E709A+G719E        18       67/F      Never       Acinar               None                       None                        None                N/A
  25       Ia           G719S           18       84/F      Never      Papillar              None                       None               Cisplatin + Gemcitabine       SD
  26       Ia        G719C+S768I      18, 20     57/M      Never       Acinar               None                       None                        None                N/A
  27       IIa       G719S+S768I      18, 20     64/F      Never       Solid                None             Carboplatin + Gemcitabine             None                N/A
  28       Ia        E709A+G719S        18       74/F      Never      Papillar              None                       None                        None                N/A
  29       IIa          G719A           18       57/M      Ever        Acinar               None                       None                        None                N/A
  30       Ia        I706T+L861Q      18, 21     59/F      Never        MIA                 None                       None                        None                N/A
  31       Ia        G719C+S768I      18, 20     54/M      Ever       Lepidic               None                       None                        None                N/A
  32       Ia        G719C+S768I      18, 20     57/F      Never       Acinar               None                       None                        None                N/A
  33       IIa          G719A           18       61/F      Never       Solid       Cisplatin + Pemetrexed              None                        None                 SD
  34       Ib        E709K+K757R      18, 19,    68/F      Never      Papillar              None                       None                        None                N/A
                       +L858R           21                                                                                                                               

F, female; M, male; MIA, minimally invasive adenocarcinoma; PD, progressive disease; PR, partial response; SD, stable disease; N/A, not applicable. Response was evaluated against the neoadjuvant or the first-line treatment.

###### Comparison of clinical characteristics between NSCLCs harboring classic activating EGFR mutations and EGFR exon 18 mutations.

  Variables          Classic activating   Mutations in    *p*
  ----------------- -------------------- -------------- -------
                         (n = 661)          (n = 34)        
  Gender                                                
   Female               420 (63.5%)        27 (79.4%)       
   Male                 241 (36.5%)        7 (20.6%)     0.067
  Age (y)                                               
   Mean                     60.0              60.9          
   SD                       10.0              11.5       0.652
  Smoking history                                       
   Ever                 140 (21.2%)        4 (11.8%)        
   Never                521 (78.8%)        30 (88.2%)    0.276
  Tumor size (cm)                                       
   ≤3                   518 (78.4%)        23 (67.6%)       
   \>3                  143 (21.6%)        11 (32.4%)    0.143
  Stage                                                 
   I                    388 (58.7%)        19 (55.9%)       
   II--IV               273 (41.3%)        15 (44.1%)    0.859
  Differentiation                                       
   Well/Moderate        522 (79.0%)        22 (64.7%)       
   Poor                 139 (21.0%)        12 (35.3%)    0.056

Classic activating mutation: EGFR exon 19 deletions and L858R point mutation; SD: standard deviation.

###### Different EGFR mutations and response to EGFR TKIs.

  Case     Mutation     Mutated exons     TKIs      Line   Response   RFS[\#](#t3-fn1){ref-type="fn"} (months)   OS[\#](#t3-fn1){ref-type="fn"} (months)
  ------ ------------- --------------- ----------- ------ ---------- ------------------------------------------ -----------------------------------------
  1       G719S+L861Q      18, 21       Gefitinib    1        PR                        65.0                                      68.0+
  6       V689L+L858R      18, 21       Erlotinib    3        PR                        20.7                                      29.4+
  18      E709K+G719C        18         Gefitinib    2        PR                       14.8+                                      14.8+
  21      G724S+S768I      18, 20       Erlotinib    2        SD                       24.2+                                      24.2+
  23      E709K+L858R      18, 21       Gefitinib    1        PR                       37.5+                                      37.5+

^\#^RFS and OS were calculated since taking TKIs.

TKIs, tyrosine kinase inhibitors; RFS, recurrence-free survival; OS, overall survival; PR, partial response; SD, stable disease.

[^1]: These authors contributed equally to this work.
